MXCT Stock Overview A life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
MaxCyte, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for MaxCyte Historical stock prices Current Share Price UK£4.11 52 Week High UK£5.55 52 Week Low UK£3.17 Beta 1.16 1 Month Change 15.77% 3 Month Change 7.87% 1 Year Change -8.67% 3 Year Change -59.27% 5 Year Change 152.15% Change since IPO 152.15%
Recent News & Updates
MaxCyte, Inc. Announces Retirement of Board Member Art Mandell Dec 23
Price target decreased by 7.1% to US$8.67 Dec 10
MaxCyte, Inc. Raises Revenue Guidance for 2024 Dec 10
MaxCyte, Inc. Raises Revenue Guidance for 2024 Dec 09
Third quarter 2024 earnings: EPS and revenues exceed analyst expectations Nov 07
MaxCyte, Inc. Updates Revenue Guidance for the Full Year 2024 Nov 07 See more updates
MaxCyte, Inc. Announces Retirement of Board Member Art Mandell Dec 23
Price target decreased by 7.1% to US$8.67 Dec 10
MaxCyte, Inc. Raises Revenue Guidance for 2024 Dec 10
MaxCyte, Inc. Raises Revenue Guidance for 2024 Dec 09
Third quarter 2024 earnings: EPS and revenues exceed analyst expectations Nov 07
MaxCyte, Inc. Updates Revenue Guidance for the Full Year 2024 Nov 07
MaxCyte, Inc. Announces Appointment of Cynthia Collins as Non-Executive Director Oct 15
MaxCyte, Inc. to Report Q3, 2024 Results on Nov 06, 2024 Oct 11
MaxCyte, Inc. Appoints Ali Soleymannezhad as Chief Commercial Officer Oct 10
Second quarter 2024 earnings: EPS and revenues exceed analyst expectations Aug 07
MaxCyte, Inc. Reaffirms Revenue Guidance for the Full Year 2024 Aug 07
New minor risk - Share price stability Aug 04
MaxCyte, Inc. to Report Q2, 2024 Results on Aug 06, 2024 Jul 10
MaxCyte, Inc.(NasdaqGS:MXCT) dropped from Russell 2500 Growth Index Jul 03
President recently bought US$489k worth of stock Jun 13
Maxcyte, Inc. Affirms Revenue Guidance for the Full Year 2024 May 09
Price target decreased by 7.1% to US$8.67 May 08
MaxCyte, Inc., Annual General Meeting, Jun 11, 2024 Apr 28
MaxCyte, Inc. to Report Q1, 2024 Results on May 07, 2024 Apr 11
MaxCyte, Inc. Reiterates Earnings Guidance for the Year 2024 Mar 14
Full year 2023 earnings: EPS and revenues exceed analyst expectations Mar 13
MaxCyte, Inc. Provides Revenue Guidance for the Fiscal Year 2023 and 2024 Mar 07
MaxCyte, Inc. to Report Fiscal Year 2023 Results on Mar 12, 2024 Feb 10
MaxCyte, Inc. Announces Departure of Cenk Sumen as Chief Scientific Officer Jan 27
MaxCyte, Inc. Provides Preliminary Financial Guidance for the Fourth Quarter and Full Year Ended December 31, 2023 Jan 09
MaxCyte, Inc. Provides Revenue Guidance Update for 2023 Dec 12
New major risk - Revenue and earnings growth Nov 10
MaxCyte, Inc. Provides Revenue Guidance for the Year 2023 Nov 10
Third quarter 2023 earnings: EPS and revenues miss analyst expectations Nov 10
MaxCyte, Inc. Provides Revenue Guidance for the Third Quarter and Full Year of 2023 Oct 07
New minor risk - Share price stability Oct 07
MaxCyte, Inc. to Report Q3, 2023 Results on Nov 08, 2023 Oct 05
Price target decreased by 9.5% to US$9.50 Oct 05
Maxcyte, Inc. Appoints Ali Soleymannezhad as Executive Vice President of Bioprocessing Sep 07
New major risk - Revenue and earnings growth Aug 11
Price target decreased by 9.5% to US$9.50 Aug 10
MaxCyte, Inc. Provides Revenue Guidance for the Year 2023 Aug 10
MaxCyte, Inc. to Report Q2, 2023 Results on Aug 09, 2023 Jul 14
First quarter 2023 earnings: EPS and revenues exceed analyst expectations May 12
MaxCyte, Inc. Provides Revenue Guidance for the Year 2023 May 11
High number of new directors Apr 02
Key Executive recently bought US$345k worth of stock Apr 01
Full year 2022 earnings released: US$0.23 loss per share (vs US$0.21 loss in FY 2021) Mar 16
MaxCyte, Inc. to Report Q4, 2022 Results on Mar 15, 2023 Feb 02
Price target decreased to US$11.67 Jan 08
MaxCyte, Inc. Appoints Patrick J. Balthrop, Sr. as Class II Director and Member of Nominating Committee and Corporate Governance Committee Dec 02
MaxCyte, Inc. Provides Revenue Guidance for 2022 Nov 12
Third quarter 2022 earnings: EPS and revenues exceed analyst expectations Nov 11
MaxCyte, Inc. to Report Q3, 2022 Results on Nov 09, 2022 Oct 13
MaxCyte expands capacity by relocating to new HQ in Maryland Sep 21
Maxcyte, Inc. Revenue Guidance for 2022 Aug 13
Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat Aug 11
MaxCyte, Inc. to Report Q2, 2022 Results on Aug 10, 2022 Jul 16
MaxCyte signs strategic platform with LG Chem Jul 12
MaxCyte, Inc.(NasdaqGS:MXCT) dropped from Russell 2000 Growth Index Jun 26
MaxCyte, Inc., Annual General Meeting, Jun 29, 2022 May 28
First quarter 2022 earnings: EPS and revenues exceed analyst expectations May 10 MaxCyte, Inc. Provides Revenue Guidance for the Full Year 2022 May 10
MaxCyte, Inc. to Report Q1, 2022 Results on May 09, 2022 Apr 21 Maxcyte, Inc. Announces CFO Changes, Effective as of April 15, 2022
MaxCyte, Inc. to Report Q4, 2021 Results on Mar 22, 2022 Feb 25
Maxcyte, Inc. Provides Preliminary Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2021 Jan 25
Independent Chairman of the Board recently bought US$222k worth of stock Nov 25
Founder recently sold US$1.3m worth of stock Nov 17
Third quarter 2021 earnings released: US$0.032 loss per share (vs US$0.037 loss in 3Q 2020) Nov 12
Second quarter 2021 earnings released: US$0.052 loss per share (vs US$0.046 loss in 2Q 2020) Sep 15
MaxCyte, Inc. Provides Preliminary Revenue Guidance for the Year 2021 Sep 15
MaxCyte: Enabling Next-Generation Cell Based Therapies, Attractive Risk-Return Profile Sep 06
Forecast breakeven pushed back to 2023 Aug 02 Shareholder Returns MXCT US Life Sciences US Market 7D -3.7% -0.9% -0.4% 1Y -8.7% -5.1% 24.8%
See full shareholder returns
Return vs Market: MXCT underperformed the US Market which returned 23.9% over the past year.
Price Volatility Is MXCT's price volatile compared to industry and market? MXCT volatility MXCT Average Weekly Movement 8.3% Life Sciences Industry Average Movement 9.1% Market Average Movement 6.3% 10% most volatile stocks in US Market 17.0% 10% least volatile stocks in US Market 3.1%
Stable Share Price: MXCT has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: MXCT's weekly volatility (8%) has been stable over the past year.
About the Company MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols.
Show more MaxCyte, Inc. Fundamentals Summary How do MaxCyte's earnings and revenue compare to its market cap? MXCT fundamental statistics Market cap US$432.86m Earnings (TTM ) -US$35.74m Revenue (TTM ) US$45.60m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) MXCT income statement (TTM ) Revenue US$45.60m Cost of Revenue US$6.39m Gross Profit US$39.21m Other Expenses US$74.94m Earnings -US$35.74m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.34 Gross Margin 85.98% Net Profit Margin -78.37% Debt/Equity Ratio 0%
How did MXCT perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/24 08:04 End of Day Share Price 2024/12/24 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources MaxCyte, Inc. is covered by 11 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Mark Massaro BTIG Matthew Hewitt Craig-Hallum Capital Group LLC Paul Cuddon Numis Securities Ltd.
Show 8 more analysts 